Idazoxan Inhibits Hyperprolactinaemia in Ovariectomized Estrogen-Treated Rats

P. Navarra; W. Eechaute; P. Preziosi; E. Lacroix

doi:10.1055/s-2007-1003602

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000025.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Horm Metab Res 1991; 23(1): 22-24
DOI: 10.1055/s-2007-1003602

Originals Basic

Idazoxan Inhibits Hyperprolactinaemia in Ovariectomized Estrogen-Treated Rats

P. Navarra² , W. Eechaute¹ , P. Preziosi² , E. Lacroix¹

¹Laboratory of Normal and Pathologic Physiology, State University of Ghent, Ghent, Belgium
²Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

Further Information

Publication History

1990

1990

Publication Date:
14 March 2008 (online)

Also available at

PDF Download Permissions and Reprints

Summary

The α2-antagonist idazoxan (IDZ) has previously been shown to inhibit hyperprolactinaemia triggered by various stimuli such as lactation, stress, serotonergic agents and morphine (Preziosi, Martire, Navarra, Pistritto and Vacca 1989; Krulich, Jurcovicova and Le 1989). In this study, we investigated the PRL-lowering activity of IDZ in ovariectomized estrogen-treated (OET) rats; since a PRL surge usually occurs in normal cycling rats on the day of proestrus, the effect of IDZ on pulsatile PRL release in intact female rats was also studied.

IDZ significantly lowered plasma PRL levels in OET rats; no elevated PRL values were observed in normal cycling rats, indicating that IDZ might inhibit PRL surges in these animals.

It is concluded that IDZ is an effective PRL-lowering agent in a number of physiological and pharmacological hyperprolactinaemic models.

Key words

Idazoxan - α2-Adrenoceptors - Prolactin